Literature DB >> 21159066

Atypical teratoid/rhabdoid tumor: short clinical description and insight into possible mechanism of the disease.

B Bikowska1, W Grajkowska, J Jóźwiak.   

Abstract

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant tumor typically appearing in childhood. Differentiation of AT/RT from other brain tumors is extremely important because of grim prognosis and necessity of more aggressive treatment. On the other hand, investigation is essential for new therapeutic agents based on continuously developing knowledge of AT/RT development mechanisms. Most AT/RT tumors have been demonstrated to harbor a chromosome 22 mutation in the region of hSNF5/INI1 gene, whose protein product participates in chromatin remodeling. Although the presence of this mutation is rather undisputable, additional molecular pathways underlying AT/RT development are poorly understood. Current paper discusses current views on molecular pathophysiology of the tumor.
© 2010 The Author(s). European Journal of Neurology © 2010 EFNS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159066     DOI: 10.1111/j.1468-1331.2010.03277.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  9 in total

Review 1.  Molecular biology of pediatric brain tumors and impact on novel therapies.

Authors:  Lindsey M Hoffman; Ralph Salloum; Maryam Fouladi
Journal:  Curr Neurol Neurosci Rep       Date:  2015-04       Impact factor: 5.081

2.  Diagnostic value of next-generation sequencing in an unusual sphenoid tumor.

Authors:  Farzad Jamshidi; Erin Pleasance; Yvonne Li; Yaoqing Shen; Katayoon Kasaian; Richard Corbett; Peter Eirew; Amy Lum; Pawan Pandoh; Yongjun Zhao; Jacqueline E Schein; Richard A Moore; Rod Rassekh; David G Huntsman; Meg Knowling; Howard Lim; Daniel J Renouf; Steven J M Jones; Marco A Marra; Torsten O Nielsen; Janessa Laskin; Stephen Yip
Journal:  Oncologist       Date:  2014-05-07

3.  Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Authors:  Anjali Singh; Xueqing Lun; Aarthi Jayanthan; Halah Obaid; Yibing Ruan; Douglas Strother; Susan N Chi; Amy Smith; Peter Forsyth; Aru Narendran
Journal:  Mol Oncol       Date:  2013-01-11       Impact factor: 6.603

4.  Mammary analogue secretory carcinoma of the parotid gland as a secondary malignancy in a childhood survivor of atypical teratoid rhabdoid tumor.

Authors:  Jennifer Woo; Raja R Seethala; S Joseph Sirintrapun
Journal:  Head Neck Pathol       Date:  2013-08-07

5.  Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.

Authors:  Aarthi Jayanthan; Delphine Bernoux; Pinaki Bose; Karl Riabowol; Aru Narendran
Journal:  Cancer Cell Int       Date:  2011-12-29       Impact factor: 5.722

6.  Atypical teratoid rhabdoid tumor: current therapy and future directions.

Authors:  Kevin F Ginn; Amar Gajjar
Journal:  Front Oncol       Date:  2012-09-12       Impact factor: 6.244

7.  Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Atypical Teratoid/Rhabdoid Tumor.

Authors:  Ki Woong Sung; Do Hoon Lim; Eun Sang Yi; Young Bae Choi; Ji Won Lee; Keon Hee Yoo; Hong Hoe Koo; Ji Hye Kim; Yeon-Lim Suh; Yoo Sook Joung; Hyung Jin Shin
Journal:  Cancer Res Treat       Date:  2016-04-01       Impact factor: 4.679

Review 8.  Atypical Teratoid Rhabdoid Tumour : From Tumours to Therapies.

Authors:  Elizabeth Anne Richardson; Ben Ho; Annie Huang
Journal:  J Korean Neurosurg Soc       Date:  2018-05-01

Review 9.  Malignant rhabdoid tumor of the liver in a middle-aged woman: a case report and literature review.

Authors:  Haikun Ye; Zirong Liu; Yamin Zhang
Journal:  BMC Gastroenterol       Date:  2022-01-21       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.